Mn3O4 nanozyme-based anti-inflammatory therapy modulates microglial phenotype by downregulating TLR4/NOX2 expression and further alleviates Alzheimer's disease pathology. The gene discussed is CYBB; the disease is early-onset autosomal dominant Alzheimer disease.